Search

Brandon Huy Pham,1 Gunay Uludag,2 Doan Luong Hien,2 Ngoc Trong Tuong Than,2 Jaclyn Joyce Hwang,2 Amir Akhavanrezayat,2 Wataru Matsumiya,2 Sherin Lajevardi,2 Jonathan Regenold,2 Muhammad Sohail Halim,2 Quan Dong Nguyen2 1Stanford University School of Medicine, Palo Alto, CA, USA; 2Spencer Center for Vision Research, Byers Eye Institute at Stanford University, Palo Alto, CA, USACorrespondence: Quan Dong Nguyen, Spencer Center for Vision Research, Byers Eye Institute at Stanford, 2370 Watson Court, Suite 200, Palo Alto, CA, 94303, USA, Tel +1 650-725-7245, Email ndquan@stanford.eduPurpose: We describe the course of a patient diagnosed with birdshot chorioretinopathy (BSCR) in early adulthood and summarize clinical findings from similar BSCR patients reported in the literature.Observations: A 37-year-old male presented to our tertiary uveitis facility with bilateral ocular discomfort, hazy vision, and floaters. Ocular examination was notable for vitritis, optic disc edema, and ovoid hypopigmented chorioretinal lesions, visible on indocyanine green chorioangiography as multiple hypocyanescent spots in the intermediate phase. Full-field electroretinography and visual evoked potential showed global retinal dysfunction and optic nerve dysfunction. Laboratory evaluations were notable only for human leukocyte antigen (HLA)-A29 positivity. The patient was diagnosed with BSCR and started on oral prednisone and eventually managed with infliximab.Conclusions and Importance: BSCR can affect patients in early adulthood. Proper diagnostic work-up, including assessing HLA-A29 positivity, is needed to manage atypical cases.Keywords: birdshot chorioretinopathy, early adulthood, human leukocyte antigen (HLA)-A29

Hashem H Ghoraba,1 Wataru Matsumiya,1,2 Hassan Khojasteh,1 Amir Akhavanrezayat,1 Irmak Karaca,1 Christopher Or,1 Negin Yavari,1 Sherin Lajevardi,1 Jaclyn Hwang,1 Cigdem Yasar,1 Diana Do,1 Quan Dong Nguyen1 1Spencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA; 2Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe, JapanCorrespondence: Quan Dong Nguyen, Spencer Center for Vision Research, Byers Eye Institute, Stanford University School of Medicine, 2370 Watson Court, Suite 200, Palo Alto, CA, USA, Tel +16507257245, Fax +1 6507368232, Email ndquan@stanford.eduPurpose: To evaluate the safety of intravenous high-dose pulse methylprednisolone succinate (IVHDM) in the management of severe or refractory non-infectious pediatric uveitis.Methods: We reviewed all uveitis patients who were ≤ 16 years of age and who received IVHDM with a dose of ≥ 500 mg per day (1– 3 days a month) for at least 3 months during their management at a tertiary care eye hospital.Results: Twenty pediatric patients with severe or refractory uveitis who received IVHDM were identified. Six patients received IVHDM either once, as a preoperative medication, or at a lower dose than 500 mg, and were excluded. The remaining 14 patients received IVHDM for at least 4 months. Age (mean±SD) was 11.9± 2.4 years and 50% were female. Duration of treatment was 14.2± 7.5 months. Thirteen patients received IVHDM in combination with other immunomodulatory therapy (IMT). Except for two outliers, IVHDM was given at a dose of 8– 25 mg/kg per infusion. Three major adverse events (AEs) occurred in two patients: a single episode of bradycardia, compression fracture following minor trauma and adrenal insufficiency. The number of AEs (major and minor) strongly correlated with duration of treatment (p=0.004) and moderately correlated with the cumulative dose/weight (p=0.051). Weight gain was associated with the use of concomit

Azadeh Mobasserian,1,* Moosa Zaidi,1,* Sohail Halim,1,2 Jaclyn Joyce Hwang,1 Jonathan Regenold,1 Amir Akhavanrezayat,1 Irmak Karaca,1,3 Hassan Khojasteh Jafari,1 Negin Yavari,1 Wataru Matsumiya,1,4 Cigdem Yasar,1,5 Ngoc Tuong Trong Than,1 Gunay Uludag,1 Diana Do,1 Hashem Ghoraba,1 Quan Dong Nguyen1 1Spencer Center for Vision Research, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, CA, USA; 2Ocular Imaging Research and Reading Center, Sunnyvale, CA, USA; 3Department of Ophthalmology, Ege University Faculty of Medicine, Izmir, Turkey; 4Division of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan; 5Department of Ophthalmology, Suleyman Demirel University, Faculty of Medicine, Isparta, Turkey*These authors contributed equally to this workCorrespondence: Quan Dong Nguyen, Spencer Center for Vision Research, Byers Eye Institute, Stanford University School of Medicine, 2370 Watson Court, Suite 200, Palo Alto, CA, 94303, USA, Tel +1 650 725-7245, Fax +1 650 736-8232, Email ndquan@stanford.eduPurpose: Diopsys® NOVA fixed-luminance flicker full-field electroretinogram (ffERG) device is a potential adjunct to conventional flicker ffERG testing for assessing cone cell function. Magnitude of measured electrical response is known to vary with pupil size in conventional ffERG testing. The index study characterizes the relationship between magnitude of measured electrical activity and pupil size, both pupil diameter and pupil area, for this device.Methods: Seventeen patients (34 eyes) with no known ocular diseases were enrolled in the study. Electrophysiologic function of cone cells was evaluated using fixed-luminance flicker ffERG before and after dilation. Linear regression models, with inter-eye correlations controlled as fixed-effects, were used to characterize the effect of pupil dilation on the magnitude of the measured responses.Results: Mean age of study patients was 33.5 (standa